Clinical Trial Update: Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+ [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update examining the safety and efficacy of radio-immunotherapy for relapsed or refractory CD22-positive B-cell acute lymphoblastic leukemia in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Radio-immunotherapy (RIT)

Snippet

Sponsor: Nantes University Hospital | Conditions: Acute Lymphoblastic Leukemia | Phase 1, Phase 2 | Status: UNKNOWN